OptiNose OPTN Stock
OptiNose Price Chart
OptiNose OPTN Financial and Trading Overview
| OptiNose stock price | 1.22 USD |
| Previous Close | 1.11 USD |
| Open | 1.11 USD |
| Bid | 0 USD x 1800 |
| Ask | 0 USD x 1200 |
| Day's Range | 1.11 - 1.17 USD |
| 52 Week Range | 1.07 - 4.3 USD |
| Volume | 945.36K USD |
| Avg. Volume | 351.82K USD |
| Market Cap | 126.51M USD |
| Beta (5Y Monthly) | -0.22183 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.32 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 4 USD |
OPTN Valuation Measures
| Enterprise Value | 173.21M USD |
| Trailing P/E | N/A |
| Forward P/E | -4.7083335 |
| PEG Ratio (5 yr expected) | -0.04 |
| Price/Sales (ttm) | 1.7244661 |
| Price/Book (mrq) | N/A |
| Enterprise Value/Revenue | 2.361 |
| Enterprise Value/EBITDA | -3.58 |
Trading Information
OptiNose Stock Price History
| Beta (5Y Monthly) | -0.22183 |
| 52-Week Change | -66.95% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 4.3 USD |
| 52 Week Low | 1.07 USD |
| 50-Day Moving Average | 1.64 USD |
| 200-Day Moving Average | 2.19 USD |
OPTN Share Statistics
| Avg. Volume (3 month) | 351.82K USD |
| Avg. Daily Volume (10-Days) | 708.37K USD |
| Shares Outstanding | 111.96M |
| Float | 74.87M |
| Short Ratio | 5.1 |
| % Held by Insiders | 7.50% |
| % Held by Institutions | 77.52% |
| Shares Short | 2.39M |
| Short % of Float | 2.46% |
| Short % of Shares Outstanding | 2.13% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | -93.16% |
| Operating Margin (ttm) | -66.61% |
| Gross Margin | 87.79% |
| EBITDA Margin | -65.95% |
Management Effectiveness
| Return on Assets (ttm) | -24.55% |
| Return on Equity (ttm) | N/A |
Income Statement
| Revenue (ttm) | 73.36M USD |
| Revenue Per Share (ttm) | 0.79 USD |
| Quarterly Revenue Growth (yoy) | -19.69% |
| Gross Profit (ttm) | 67.01M USD |
| EBITDA | -48384000 USD |
| Net Income Avi to Common (ttm) | -68347000 USD |
| Diluted EPS (ttm) | -0.68 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 83.93M USD |
| Total Cash Per Share (mrq) | 0.75 USD |
| Total Debt (mrq) | 130.62M USD |
| Total Debt/Equity (mrq) | N/A |
| Current Ratio (mrq) | 0.674 |
| Book Value Per Share (mrq) | -0.659 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -58794000 USD |
| Levered Free Cash Flow (ttm) | -33608376 USD |
Profile of OptiNose
| Country | United States |
| State | PA |
| City | Yardley |
| Address | 1020 Stony Hill Road |
| ZIP | 19067 |
| Phone | 267 364 3500 |
| Website | https://www.optinose.com |
| Industry | Drug Manufacturers-Specialty & Generic |
| Sector(s) | Healthcare |
| Full Time Employees | 141 |
OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device. OptiNose, Inc. has a license agreement with Currax Pharmaceuticals LLC for the commercialization of Onzetra Xsail; and Orexia Therapeutics to develop, manufacture, import, and sale products containing orexin receptor agonist and/or orexin receptor positive modulator molecules for the treatment, diagnosis, or prevention of human diseases or conditions associated primarily with orexin receptor agonism and orexin receptor positive modulation. The company was founded in 2000 and is headquartered in Yardley, Pennsylvania.
Q&A For OptiNose Stock
What is a current OPTN stock price?
OptiNose OPTN stock price today per share is 1.22 USD.
How to purchase OptiNose stock?
You can buy OPTN shares on the NasdaqGS exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for OptiNose?
The stock symbol or ticker of OptiNose is OPTN.
Which industry does the OptiNose company belong to?
The OptiNose industry is Drug Manufacturers-Specialty & Generic.
How many shares does OptiNose have in circulation?
The max supply of OptiNose shares is 112.65M.
What is OptiNose Price to Earnings Ratio (PE Ratio)?
OptiNose PE Ratio is now.
What was OptiNose earnings per share over the trailing 12 months (TTM)?
OptiNose EPS is -0.32 USD over the trailing 12 months.
Which sector does the OptiNose company belong to?
The OptiNose sector is Healthcare.
OptiNose OPTN included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 16175.09 USD — |
-1.62
|
3.94B USD — | 16125.33 USD — | 16341.46 USD — | — - | 3.94B USD — |
| Stlmt ID NASDAQ Biotechnology NBX | 4604.4 USD — |
-2.98
|
— — | 4555.41 USD — | 4917.8 USD — | — - | — — |
| NASDAQ Global Select Market Com NQGS | 7876.03 USD — |
-1.61
|
— — | 7852.08 USD — | 7955.84 USD — | — - | — — |
| NASDAQ Biotechnology NBI | 4195.13 USD — |
-2.14
|
— — | 4174.1 USD — | 4266.29 USD — | — - | — — |
| NASDAQ HealthCare IXHC | 958.68 USD — |
-2.07
|
— — | 954.08 USD — | 972.42 USD — | — - | — — |
- {{ link.label }} {{link}}